Surf Bio to Showcase SnapShot™ Technology at PODD 2025
Surf Bio, a leading biopharmaceutical company, is excited to present its groundbreaking SnapShot™ technology at a major industry event. The focus of this presentation will be the ability of SnapShot to deliver ultra-high concentration doses of monoclonal antibodies (mAbs) and biologics through standard subcutaneous injection methods.
Revolutionizing Biologics Delivery
The upcoming presentation at the Partnership Opportunities in Drug Delivery 2025 Conference, scheduled for late October, will highlight SnapShot's innovative design and practicality in the modern healthcare landscape. This event is a pivotal opportunity for Surf Bio to illustrate how its technology can cater to the growing demand for patient-centered and decentralized care.
Details of the Presentation
Surf Bio's CEO, Bryan Mazlish, is set to deliver an insightful talk titled "Surf SnapShot™ Technology: Ultra-Concentrated Subcutaneous Biologics via Standard Manufacturing Processes." This presentation will occur on the first day of the conference, shedding light on the scientific principles behind SnapShot, its performance, and its commercial viability. It is an exciting moment for the company as it aims to reshape biologic treatments.
Key Advantages of SnapShot™ Technology
SnapShot is ingeniously designed to enable the delivery of ultra-high concentrations of biologic therapies using a single injection method. By utilizing Surf Bio's proprietary surfactant polymer technology, the platform can achieve protein concentrations of up to 600 mg/mL and deliver doses as high as 1,000 mg. This addresses several longstanding challenges associated with biologic formulation and delivery.
Impact on Treatment Accessibility
As Bryan Mazlish explains, despite the cutting-edge advancements in biologic therapies, many still rely heavily on lengthy intravenous infusions. SnapShot offers a transformative option—allowing patients to receive their treatments swiftly and conveniently at home. This innovation promises to enhance not only treatment accessibility but also the economic aspects of biologic therapies, significantly improving patient experiences.
Networking Opportunities at PODD 2025
Surf Bio will engage in various one-on-one meetings during the conference, offering industry stakeholders the chance to explore potential partnerships that can leverage the SnapShot platform for mutual benefit. The company is keen to connect with pharmaceutical and biotechnology leaders, fostering dialogue to promote advancements in drug delivery.
About Surf Bio
Surf Bio is at the forefront of biopharmaceutical innovation, dedicated to enhancing the delivery system for antibodies and biologics through its advanced SnapShot™ technology platform. This proprietary polymer facilitates the creation of high-concentration formulations that can be administered easily with standard autoinjectors. The company, founded by experienced professionals with a strong background in biotechnology, is driven by the objective to bring revolutionary drug delivery solutions to the market.
Frequently Asked Questions
What is SnapShot™ Technology?
SnapShot™ Technology is an innovative platform designed by Surf Bio to enable the delivery of ultra-high concentration biologics via standard subcutaneous injections.
When will Surf Bio present at PODD 2025?
Surf Bio's CEO will present on October 27, 2025, detailing the benefits and science behind SnapShot technology.
What are the advantages of using SnapShot™ Technology?
SnapShot allows for faster, more convenient patient treatment options, reducing the need for lengthy intravenous infusions.
How does SnapShot™ help in biologic formulation?
The platform addresses challenges in biologic formulation by allowing high concentrations of the drug product that can be effectively delivered through autoinjectors.
How can I learn more about Surf Bio?
For more information about Surf Bio and its offerings, visit their official website.
